Living Cell Technologies considers 'medical tourism' if Parkinson's therapy trial succeeds

Living Cell Technologies considers 'medical tourism' if Parkinson's therapy trial succeeds
Fiona Rotherham
By Fiona Rotherham Aug. 26 (BusinessDesk) - Australasian biotech company Living Cell Technologies plans to treat patients for Parkinson’s disease under a “medical tourism” model if its clinical trial under way in Auckland succeeds next year. The phase 11b clinical trial of 18 patients is underway at the University of Auckland and Mercy Hospital on its regenerative cell therapy NTCELL, which would be the world’s first disease-modifying treatment for Parkinson’s. Results are expected mid-next year from the escalating dosage clinical tria...